







































At an age when proper nutrition is a fundamental health 
requirement, almost half the elderly people in developed 
countries are not adequately nourished.  By the widely 
used Mini Nutritional Assessment, the reported 
prevalence of nutritional risk in older subjects is 
approximately 45% in the community, with higher 
values in domiciliary care settings or hospitals and 84% 
to 100% in residential care facilities [1]. Malnutrition is 
defined as a state in which a deficiency, excess or 
imbalance of energy, protein and other nutrients causes 
adverse effects on body form, function and clinical 
outcome [2].  Excess  caloric  intake  or consumption  of  
 
 







































palatable energy-dense foods increases fat accumulation 
and vulnerability to a range of age-related diseases, 
including type 2 diabetes,  cardiovascular disorders, and 
cancer. A substantial number of older people in 
westernized countries are overweight. Although the 
increase in the relative risk for death that is associated 
with being obese is not as great in older subjects as it is 
in young adults, functional capacity, mobility and 
quality of life are significantly reduced in the obese 
elderly [3]. On the other side, undernutrition is a 
common feature among aged individuals, due to 
multiple reasons that include reduced appetite and food 
intake – the physiologic ‘‘anorexia of aging’’ – and 























slows  the  progression  of  age‐related  diseases  and  extends  the  lifespan  of  many  species.  Identification  of  strategies
mimicking key CR mechanisms – increased mitochondrial respiration and reduced production of oxygen radicals – is a hot
topic in gerontology. Dietary supplementation with essential and/or branched chain amino acids (BCAAs) exerts a variety
of beneficial  effects  in  experimental  animals  and humans  and has been  recently demonstrated  to  support  cardiac  and
skeletal  muscle  mitochondrial  biogenesis,  prevent  oxidative  damage,  and  enhance  physical  endurance  in  middle‐aged
mice,  resulting  in  prolonged  survival. Here we  review  recent  studies  addressing  the  possible  role  of  BCAAs  in  energy
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absorption and other age-related medical, psychological 
and social changes [1, 2]. Inadequate nutritional intake 
may conduct to a global functional decline referred to as 
frailty, a newly recognized geriatric syndrome due to 
excess demand imposed upon reduced capacity [4]. 
Particularly, potein-energy undernutrition is associated 
with reduced strength, decreased bone mass, immune 
dysfunction, anemia, impaired cognitive function, poor 
wound healing, delayed recovering from surgery and 
higher hospitalization rate and is a strong independent 
predictor of mortality in elderly people [3].  
 
Geriatric nutrition research aims to decipher the 
molecular mechanisms involved in the effects of dietary 
nutrients and to clarify their efficacy in the attainment 
of healthy aging. Several studies focused in particular 
on the effects of varying nutrient supply on animal and 
human longevity, with responses strongly dependent on 
genotype, age, nutrients, and regulation of nutrient-
sensing pathways  [5, 6].  
 
Calorie restriction (CR), a low-calorie dietary regimen 
without malnutrition, decreases the incidence of several 
age-associated disorders and is considered the gold-
standard, non-genetic approach for lifespan extension [7]. 
A body of evidence in several organisms demonstrates 
that an increase in mitochondrial activity, together with 
activation of the reactive oxigen species (ROS) defense 
system, is associated with the salutary effects of the CR 
regimen, [7, 8]. Although it has beneficial effects in 
humans [9], long-term CR requires a major commitment 
of will power and its possible disadvantages remain to be 
determined, particularly in the elderly [10]. Therefore, 
the concept of calorie restriction mimetics – that could 
provide the health benefits of CR without reduction in 
food intake – has become a hot area of investigation 
within gerontology [10].  
 
Previous observations in yeast suggested that the 
branched-chain amino acids (BCAAs)  leucine, 
isoleucine, and valine might be potential candidates in 
promoting survival [11]. We recently demonstrated that 
long-term dietary supplementation with a specific 
BCAA-enriched amino acid mixture (BCAAem) 
increased average lifespan of male mice [12]. This was 
accompanied by increased mitochondrial biogenesis and 
sirtuin 1 (SIRT1) expression and by up-regulated ROS 
defense system, with reduced oxidative damage, both in 
cardiac and skeletal muscles of middle aged mice [12]. 
The present article will analyse existing knowledge 
from various model organisms, from yeast to mammals, 
as well as from human studies, as a contribution to 
explore the possible effects of promoting mitochondrial 
function through BCAA supplementation on the health 




The budding yeast, Saccharomyces cerevisiae, has been 
widely used for the identification of genes and cellular 
and biochemical pathways that affect the aging process.  
In unicellular yeast, aging mechanisms can be 
investigated by measuring replicative lifespan (RLS, the 
number of daughters produced by each dividing mother 
cell), or chronological lifespan (CLS, the capacity of 
stationary G0 cultures to maintain viability over time) 
[13]. CR, that is known to lengthen the mean and 
maximum lifespan of many species [7], extends both 
RLS and CLS [14-16]. The NAD+-dependent histone 
deacetylase, Sir2, a well-characterized RLS factor [17], 
is required for yeast RLS extension by CR [14]. Both 
yeast RLS and CLS are also affected by genetic 
interventions on lifespan effectors related to nutrient 
signaling, i.e., deletion of the yeast Sch9 gene [which is 
homologous to the mammalian Akt/PKB implicated in 
the insulin-like growth factor (IGF) signaling] and  
mutations in the target of rapamycin (TOR) signaling 
pathway [18-20]. Saccharomyces cerevisiae is a 
facultative anaerobe that, under standard laboratory 
growth conditions (2% glucose), generates ATP largely 
by fermentation. Interestingly, deletion of the TOR1 
gene and CR cause a shift in glucose metabolism from 
fermentation –  based on anaerobic glycolysis –  toward 
respiration – based on oxidative metabolism involving 
the electron transport chain (ETC) – in both lifespan 
models [15, 20, 21], revealing a strong link between 
prolongevity effects and mitochondrial function. 
 
In detail, moderate CR (modelled in yeast by reducing 
the glucose content of the media from 2% to 0.5%) 
leads to a 25% increase in the RLS together with 
increased transcription of respiratory genes and a higher 
rate of oxygen consumption [21]. Overexpression of the 
transcription factor Hap4, that causes a switch from 
fermentation to respiration, is sufficient to increase 
yeast RLS by 35% [21]. Gowth at 0.5% glucose fails to 
extend RLS in cyt1 yeast mutants with impaired 
electron transport, suggesting that the metabolic shift 
toward respiration is necessary for lifespan extension 
mediated by CR [21].  This finding has been questioned 
by other studies, showing that increased respiration is 
not required for RLS extension by CR [22], in that CR 
at very low (0.05%) glucose concentrations increased 
lifespan in yeast strains lacking mtDNA (ρ0 cells) or in 
cyt1 mutants [22]. However, the fact that alternate 
pathways promoting longevity are induced in yeast 
strains lacking respiratory capacity does not negate the 
role of mitochondrial respiratory function in CR-
induced prolongevity when the organelles are functional 
[23]. An increase in genes involved in respiratory 
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metabolism and mitochondrial function and an 
induction of tricarboxylic acid (TCA) cycle, at least 
partially due to Hap4 up-regulation, has been recently 
reported to play a striking role in yeast CR lifespan 
extension models (0.1% glucose or elimination of 
nonessential amino acids) [24]. 
 
Saccharomyces cerevisiae has also served as a model 
organism to investigate the role of amino acid 
homeostasis in aging. It has been found that low levels 
of essential amino acids reduce CLS. Further, CLS has 
been recently studied in yeast grown in media 
supplemented with different amino acids. Increased 
availability of leucine, isoleucine and valine extended 
CLS and reduced the expression of GCN4, a 
transcriptional regulator of general amino acid control 
pathway, which regulates cellular amino acid 
homeostasis at a global level [11]. Conversely, the 
amino acid-mediated CLS extension was suppressed by 
constitutive overexpression of GCN4 [11]. The fact that 
leucine, isoleucine and valine were most important for 
CLS points to a special status for the BCAAs during 
aging. Accordingly, deletion of LEU3, a zinc finger 
transcription factor involved in  BCAAs synthesis, 
dramatically increased CLS in the absence of amino 
acid supplements.  
 
Caenorhabditis elegans 
The nematode Caenorhabditis elegans (C. elegans) 
normally has a lifespan of about three weeks. The dauer 
larva, however, lives several times longer. In addition, 
several C. elegans mutants have increased longevity 
[25].  
 
Surprisingly, a large class of C. elegans mutants with 
either genetic or RNA interference (RNAi)-mediated 
disruptions in genes essential for the function of 
mitochondrial ETC – the so-called Mit mutants – are 
long-lived (see [23] for review). The isp-1 mutant bears 
a missense mutation in the Rieske iron sulphur protein 
(ISP), a subunit of the mitochondrial complex III. This 
mutant shows decreased mitochondrial respiration, low 
oxygen consumption, and prolonged lifespan [26]. Also 
the clk-1 mutants, with defective ubiquinone (UQ9), the 
electron acceptor in complex I-dependent respiration, 
have increased lifespan [27]. The underlying cause for 
the increased lifespan of clk-1 is a point of debate. In 
clk-1 mutants, a ubiquinone intermediate  (demetho-
xyubiquinone, DMQ9) accumulates to functionally 
replace ubiquinone, so that clk-1 worms respire almost 
normally and show ATP levels unchanged or even 
higher than those of the wild type strain, strongly 
implying that their longevity is not the direct 
consequence of decreased energy metabolism [27]. 
Others have proposed that, despite a specific defect in 
complex I-dependent respiration and equal or increased 
ROS production, mitochondria of clk-1 mutants 
scavenge ROS more effectively than wild type due to 
the presence of DMQ9, leading to reduced oxidative 
damage [28]. It has to be noticed that not all mutations 
that disrupt the ETC in C. elegans lead to an increase in 
lifespan. The gas-1 mutants are characterized by low 
complex I-specific respiration, intense oxidative 
damage in mitochondrial proteins and very short 
lifespan [28]. The mev-1(kn-1) mutant, with a deletion 
in a subunit of complex II has a shortened lifespan [29]. 
Moreover, deletion of phb-1 or phb-2 (coding for 
mitochondrial prohibitins) has been found to influence 
ATP levels, animal fat content, mitochondrial 
proliferation and lifespan in a genetic background- and 
age-specific manner [30].  
 
Prolongevity effects of CR have been described in C. 
elegans models. Up-regulated or unchanged metabolic 
rate, respectively, have been initially described in long-
lived eat mutants (having a feeding defect) and calorie 
restricted worms [31]. More recently, it has been 
demonstrated that CR-mediated C. elegans lifespan 
extension requires an increase in the respiration rate 
(whole-body oxygen consumption) [32]. Accordingly, 
specific restriction of intracellular glucose by 2-deoxy-
glucose treatment also extends lifespan in worms by 
promoting mitochondrial respiration and an antioxidant 
response [33]. 
 
The latest way to investigate long-lived worms 
distinctive features is metabolite profiling, also called 
metabolomics. By this approach, Fuchs and coworkers 
[25] simultaneously studied different models of long-
lived worms, i.e., dauer larvae, several daf-2 mutants 
[affecting the insulin/IGF-1 (IIS) signaling pathway], 
and ife-2 mutants (with disrupted eukaryotic translation 
initiation factor, eIF4E). The metabolic responses of all 
these mutants were similar, allowing to identify a 
“metabolic signature” of long-life in worms. The most 
striking response was the up-regulation of the BCAAs 
isoleucine, leucine and valine in long-lived daf-2 and 
ife-2 mutants.  The longevity prolonging effects of 
DAF-2/IIS pathway suppression is mediated by the 
activation of the FOXO transcription factor DAF-16. To 
find out whether the metabolite changes were also 
DAF-16 dependent, metabolic profiling of wild type 
worms was compared to that of the daf-2 mutants, the 
daf-16 mutants, or double-mutant worms. Of interest, 
isoleucine, valine, and leucine changes showed the 
classic pattern of DAF-16 dependence, making BCAAs 
strong candidates for having a causal role in long life 
[25]. A more recent metabolomic study brought further 
evidence that BCAA levels are increased in a DAF-16-
dependent manner in long-living daf-2 mutants [34]. 
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Like other animals, C. elegans cannot synthesize 
BCAAs, so that their levels depend on changes in 
protein turnover or in BCAAs catabolism. Key 
regulators of BCAA catabolic pathway are BCAA 
aminotransferase (BCAT) and the branched-chain α-
ketoacid dehydrogenase (BCKDH) complex [35]. It has 
been hypothesized that the down-regulation of genes 
encoding for the BCKDH complex might be responsible 
for the accumulation of BCAAs in long-lived worms 
[25]. Altered transcript levels of various genes involved 
in BCAA metabolism have been found in long-lived 
mutants by other authors [34]. Although strong BCKDH 
inactivation causes severe embryonic and larval 
phenotypes in C. elegans and maple syrup urine disease 
in humans, it has been suggested that partial down-
regulation of the BCKDH complex or subtle elevation 
of BCAA levels by diet might confer long life [25]. 
 
Drosophila melanogaster 
The fruit fly Drosophila melanogaster has a relatively 
short lifespan and has been extensively used as a model 
organism for aging studies. Early reports revealed 
reduced mitochondrial number and mitochondrial 
structural changes in the aged Drosophila [36].  The 
expression levels of various transcription factors 
essential for mtDNA replication, including 
mitochondrial DNA transcription factor A (Tfam), are 
decreased in old flies. Further, aged flies have reduced  
transcripts of genes of the ETC and the TCA cycle and 
reduced ATP synthesis [37]. Conversely, the genes 
involved in oxidative phosphorylation are up-regulated 
in long-lived Drosophila overexpressing a small 
mitochondrial chaperone, Hsp22 [38].  
 
Engineering fruit flies to overexpress a single-subunit 
mitochondrial respiratory complex from yeast showed 
tissue-specific effects on longevity. Overexpression of 
the NADH–ubiquinone oxidoreductase (NDI1) of 
Saccharomyces cerevisiae in the adipose tissue of the 
fruit fly was found to exert a negative impact on 
longevity, while neuronal NDI1 overexpression resulted 
in life extension [39]. Ubiquitous expression of NDI1 
significantly increased fly longevity [40], supporting the 
idea that increased respiration can retard the Drosophila 
aging process. Increased mitochondrial activity plays 
also a causative role in CR-mediated extension of 
Drosophila lifespan, since knock-down of either 
complex I or IV subunits leads to diminished lifespan 
extension under CR [41].  
 
Mitochondria are critical in providing metabolites for 
the de novo synthesis of nonessential amino acids. 
Drosophila larvae grown in low yeast food, thus on 
amino acid starvation, showed strongly reduced 
mitochondrial abundance, mitochondrial respiratory 
proteins and respiration activity in larval fat body, the 
fly adipose/liver tissue [42]. This correlated with 
reduced expression of enzymes involved in glutamine 
metabolism [42], strongly suggesting that the amino 
acid metabolism is coordinated with mitochondrial 
abundance and activity. The Drosophila transcription 
factor Delg was proposed to coordinate mitochondrial 
functions according to nutrient availability, and to 
adjust the synthesis of nonessential amino acids to the 
uptake of essential amino acids [42].  
 
Mus musculus  
Despite the interest of results obtained in lower 
organisms, use of mammalian models, such as mice, is 
likely to be more relevant for understanding the aging-
related processes that occur in humans. Naturally long-
lived mouse mutants and various genetically altered 
mice with extended lifespan have been studied [43]. A 
body of evidence indicated the GH/IGF-1 axis as a 
major contributor to longevity effects in mice. Further 
evidence implicated increased capacity to resist 
oxidative damage in mice survival [43], particularly 
thanks to studies on p66(Shc), a crucial regulator of 
ROS levels whose deletion in mice prolongs lifespan 
(See Trinei et al. [44] for recent review). Efficient 
renewal of functional mitochondria is known to reduce 
mitochondrial ROS production [7]. Interestingly,  
mutations affecting GH/IGF-1 signaling induce 
mitochondrial gene expression and oxidative 
metabolism in mice [45-46].  
 
The life-extending effects of the CR regimen in rodents 
are well known [7]. We first demonstrated that CR, by 
feeding mice on alternate days, promotes mitochondrial 
renewal in several tissues, mainly by increasing the  
expression of peroxisome proliferator-activated receptor 
γ coactivator 1α (PGC-1α) [8], a powerful regulator of 
mitochondrial biogenesis and of the reactive ROS 
defense system [47]. CR also induced the expression of 
endothelial nitric oxide synthase (eNOS) and SIRT1, 
the mammalian orthologue of the yeast Sir2 gene linked 
to lifespan extension, enhanced mitochondrial 
biogenesis and decreased ROS production [8]. Our 
observations have been subsequently confirmed by 
others [48, 49], also in humans [50]. The CR effects 
were blunted in eNOS-null mutant (eNOS-/-) mice [8]. 
Interestingly, eNOS-/- mice have defective 
mitochondrial biogenesis, reduced SIRT1 expression [8, 
51, 52] and display metabolic derangements, age-related 
diseases and shortened lifespan [53, 54].  
 
The relevance of boosting mitochondrial function to 
preserve mammalian health  and longevity has been 
recently proved by Safdar et al. [55]. In a strain of mice 
prone to mtDNA damage and with reduced lifespan 
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(i.e., the mtDNA mutator mouse, designated the PolG 
mouse, a model of progeroid aging that exhibits 
elevated mtDNA point mutations), a regime of 
endurance training induced mitochondrial biogenesis, 
increased mitochondrial respiratory capacity, and 
prevented mtDNA damage. Furthermore, the trained 
mice no longer exhibited premature mortality or other 
symptoms associated with accellerated aging, including 
fat loss, muscle loss, anemia, and graying fur. 
 
Three of the seven mammalian sirtuins (SIRT3, SIRT4, 
and SIRT5) are targeted to mitochondria and can their 
expression be differently modulated by the CR regimen 
[56-58]. Studies in SIRT3 and SIRT5 mutant mice, that 
are prone to age-related disorders [59] have recently 
provided unexpected links among CR-related 
mitochondrial changes and amino acid metabolism (see 
below). 
 
Antiaging effects of dietary BCAA supplementation 
in mice 
 
In search for CR-mimetic compounds, we recently 
investigated the effects of a balanced amino acid 
mixture with a high content of branched-chain and other 
essential amino acids (BCAA-enriched mixture, 
BCAAem; % composition: leucine 31.3, lysine 16.2, 
isoleucine 15.6, valine 15.6, threonine 8.8, cysteine 3.8, 
histidine 3.8, phenylalanine 2.5, methionine 1.3, 
tyrosine 0.7, tryptophan 0.5) which had been found to 
improve age-related disorders in animals and humans 
(see below). We demonstrated that BCAAem oral 
supplementation (1.5 mg/g body weight/day beginning 
at 9 months) increases the average, but not maximal 
lifespan of male mice [12]. Along with increased 
survival, BCAAem-supplemented middle-aged (16 
months) mice showed up-regulated PGC-1α and SIRT1 
expression and enhanced  mitochondrial biogenesis and 
function in cardiac and skeletal muscles but not in 
adipose tissue or liver. Further, the BCAAem preserved 
muscle fiber size and improved physical endurance and 
motor coordination in middle-aged mice [12]. Notably, 
BCAAem was unable to affect muscle mitochondrial 
density and function and failed to extend average 
lifespan in eNOS-/- mice. The prolonged survival due to 
BCAAem supplementation was also associated with 
increased expression of genes involved in antioxidant 
defense and marked reduction of ROS production in 
cardiac and skeletal muscles of wild type but not eNOS-
/- mice. Of interest, BCAAem-mediated effects were 
even more remarkable in long-term exercise-trained 
(running 30 to 60 min 5 days/week for 4 weeks) middle-
aged mice. In young animals (4-6 months old), the 
mixture was ineffective. 
Which mechanisms are involved in the observed 
BCAAem effects? mTOR complex 1 (mTORC1; 
mammalian TOR [mTOR] in complex with raptor) is a 
key regulator of protein synthesis and cell growth in 
response to nutrient amino acids. BCAAs increase 
mTORC1 activity [60], which favours cell oxidative 
capacity [61] and PGC-1α-mediated mitochondrial gene 
expression [62]. We found that BCAAem activated 
mTOR and its downstream signals and that the 
mTORC1 inhibitor rapamycin antagonized the 
mitochondrial biogenesis effects of  BCAAem in 
cardiomyocytes [12]. We also found evidence 
suggesting that BCAAem-activated mTOR signaling 
might enhance mitochondrial biogenesis partly through 
increasing the NO generating system. Moreover, eNOS 
gene silencing decreased the mTOR activation by 
BCAAem in cells and BCAAem supplementation was 
unable to activate mTOR signaling in eNOS-/- mice 
[12].  Thus, a positive feedback mechanism between 
eNOS and mTOR could promote the BCAAem effects. 
How amino acids influence and activate mTORC1 was 
not been well delineated until a most recent study, 
which established inositol polyphosphate multikinase 
(IPMK) as a key determinant of leucine- or total amino 
acid-mediated signaling to mTORC1 in mice [63]. 
Amino acid-stimulated mTOR activation occurs 
independently of IPMK’s catalytic activity. Instead, 
IPMK acts by stabilizing the mTOR-raptor association 
in the mTORC1 complex [63].  
 
We did not specifically investigate the contribution of 
enhanced mTOR signaling in BCAAem-mediated 
increase of mice average survival. Interestingly, 
selective knockout of either mTOR or the mTORC1 
component raptor in skeletal muscle decreased 
oxidative capacity, mitochondrial gene expression, and 
survival [64, 65]. However, reduced TOR signaling is 
thought to be a putative mechanism mediating lifespan 
extension by CR (see [66] for review). Mice with 
deletion of the mTOR substrate ribosomal S6 protein 
kinase (S6K) have increased lifespan [67]. Further, 
chronic rapamycin treatment in mice exerts 
prolongevity effects [68], yet this finding does not 
conclusively prove that mTOR inhibition is the 
mechanism involved in rapamycin-mediated life 
extension. Notably, rapamycin was unable to increase 
Drosophila lifespan [69]. Moreover, mTOR inhibition-
mediated lifespan extension displays a gender effect 
clearly distinguishable from CR. Unlike CR, rapamycin 
is more efficacious in female than in male mice [68], 
while S6K deletion increases  lifespan only in females 
but not in males [67]. The gender-specific pattern of 
mTOR inhibition in aged individuals remains a problem 
to be solved [70]. Again, the role of mTOR in CR is 
tissue specific. CR reduces mTOR signaling in liver 
  
www.impactaging.com                  468                                             AGING,  May 2011, Vol.3 No.5
[71] but increases it in WAT and heart [72]. Further, the 
CR-mediated increase of mitochondrial function in 
different tissues [8] is not consistent with reduced 
mTOR signaling. In addition, recent evidence indicates 
that mTOR signaling is down- or up-regulated 
depending of age and the type of CR regimen [73]. All 
in all, the role of mTOR in CR mechanisms is complex 
and not yet conclusively clarified [74]. With this in 
mind, more work needs to be done to address the 
possible contribution of mTOR in BCAAem 
prolongevity effects.  
 
Why does the BCAAem promote mitochondrial 
biogenesis in metabolically active tissues and what is 
the relationship between this effect and the CR-induced 
changes in mitochondrial function? Conclusive answers 
are not available yet, but a sound hypothesis can be put 
forward. First, amino acids are important precursors of 




































catabolism leads to production of ammonia, which is 
metabolized via the urea cycle, whose first two steps 
occurr in the mitochondrial matrix (Fig. 2). Thus, the 
amino acid supplementation could induce mitochondrial 
biogenesis to promote catabolism of amino acid 
themselves. Interestingly, Nakagawa et al.  [58] 
demonstrated that during long-term CR or a high 
protein diet, the mitochondrial SIRT5 deacetylates and 
activates carbamoyl phosphate synthase 1, the first and 
regulated step of urea cycle. Accordingly, Hallows et al. 
[59] have more recently demonstrated that the 
mitochondrial deacetylase SIRT3 directly regulates 
ornithine transcarbamoylase activity, the second step of 
the urea cycle, thus promoting the amino acid 
catabolism during CR. These findings suggest that the 
amino acid-induced mitochondrial biogenesis might be 
functional to amino acid catabolism and that amino 
acids might be, either directly or indirectly, related to 







































to one among  the  seven metabolic  intermediates  (pyruvate, α‐ketoglutarate,  succinyl‐CoA,  fumarate, oxaloacetate, acetyl‐CoA or
acetoacetate). Thus, amino acids may be divided into two groups, on the basis of their catabolic pathways: 1) gluconeogenic amino






















































































































Figure  2.  Catabolism  of  branched‐chain  amino  acids.  Starvation  and  exercise  stimulate  protein  breakdown,  thereby
increasing  the  concentrations  of  branched‐chain  amino  acids  (BCAAs)  in  adipose  and  muscle  cells.  The  BCAAs  are
transaminated  in  muscle  mitochondria  by  branched‐chain  aminotransferase  (BCAT),  and  branched‐chain  α‐keto  acids
(BCKAs, especially α‐keto acid from leucine) inhibit branched‐chain α‐keto acid dehydrogenase kinase, resulting in elevation
of the active state of the rate limiting enzyme branched‐chain α‐keto acid dehydrogenase complex (BCKDH). Recent results





www.impactaging.com                   470                                             AGING,   May 2011, Vol.3 No.5
Health effects of BCAAs in mammals 
 
For decades, dietary supplementation with amino acids 
has been proposed in various physiological or 
pathological conditions. Based on the recent progress in 
our understanding of the BCAA cell signaling and in 
vivo metabolism, and on accumulating experimental 
results, the concept that dietary BCAA supplementation 
might have health effects is now experiencing a major 
revival (see [75] for review). Latest evidence from basic 
and clinical studies might extend the use of specific 
amino acid mixtures for the prevention and/or treatment 
of diverse human disorders.  
 
Animal studies: an update 
The effects of BCAA intake have been investigated in a 
number of disease models, including obesity and 
metabolic disorders,  liver disease, impaired immunity, 
muscle atrophy, cancer, and a variety of injury 
(postoperative,  trauma, burn, and sepsis) [75]. Here we 
will briefly revise the most recent developments of this 
topic.  
 
First of all, BCAAs appear to have unique obesity-
related effects. BCAAs, and in particular leucine, 
increase fat leptin secretion [76], decrease food intake 
and body weight via mTOR signaling [77], and improve 
muscle glucose uptake and whole body glucose 
metabolism [78]. However, obese rodents (ob/ob mice 
and fa/fa Zucker rats) exhibit elevated plasma BCAA 
levels [78]. To explore loss of catabolic capacity as a 
potential contributor to the obesity-related rises in 
BCAAs, She et al. [78] assessed possible changes in the 
first two enzymatic steps of BCAA catabolism, namely, 
BCAT and the BCKDH complex. They found tissue-
specific alterations in BCAA catabolic enzymes, 
involving a decline of  BCKDH E1α in liver and 
adipose tissue, but not in muscle, possibly contributing 
to the rise in plasma BCAAs in obesity. In a separate 
series of experiments, the same investigators generated 
mice in which the gene encoding the BCAT2 isozyme 
was disrupted [79]. They found that rises in plasma 
BCAAs were associated with improvements in glucose 
tolerance and resistance to diet-induced obesity in these 
animals. The authors proposed that increased protein 
synthesis and degradation would contribute directly to 
increased energy expenditure in mice lacking peripheral 
BCAA metabolism. These findings suggest that the 
increased BCAA levels in obese animals might be 
compensatory to obesogenic stimuli. 
 
Actually, controversy exists about the effects of 
increasing dietary leucine on insulin sensitivity. For 
example, Zhang and colleagues have demonstrated that 
an increased leucine dietary intake improves the whole-
body glucose metabolism in mice maintained on a high-
fat diet [80]. By contrast, in a recent study, leucine 
deprivation was observed to increase whole-body 
insulin sensitivity [81]. Leucine deprivation improved 
hepatic insulin sensitivity by activating general control 
nonderepressible GCN2, decreasing mTOR/S6K1 and 
activating AMP-activated protein kinase (AMPK) 
signaling. Again, leucine deprivation improved insulin 
sensitivity under insulin-resistant conditions [81]. 
Noteworthy, Noguchi et al. [82] designed a novel diet 
with an elevated ratio of essential to nonessential amino 
acids (high-E/N diet). Dietary proteins in the high-E/N 
diet were partially replaced with a mixture of free 
ketogenic essential amino acids (leucine, isoleucine, 
valine, lysine and threonine) without altering dietary 
carbohydrate and fat content. This dietary amino acid 
manipulation improved glucose tolerance, decreased 
lipogenesis and prevented hepatic steatosis in diet-
induced obese mice, and was suggested as a novel 
preventive and therapeutic approach for non-alcoholic 
fatty liver disease. Accordingly, in a recent study, rats 
orally administered an amino acid mixture (containing 
cysteine, methionine, valine, isoleucine and different 
concentrations of leucine) together with a high-glucose 
solution, have shown an improved glucose tolerance as 
compared to non-supplemented animals [83]. Overall, 
these results would suggest that specific mixtures of 
amino acids, rather than a single amino acid 
supplement, may be more efficacious in lowering the 
blood glucose response to a glucose challenge. 
 
A promising area of preclinical research is regarding the 
effects of BCAAs on skeletal muscle atrophy. We 
observed that BCAAem intake preserves muscle fiber 
size and improved physical endurance and motor 
coordination in middle-aged mice [12]. Accordingly, an 
amino acid mixture with BCAAem composition has 
been found to improve sarcopenia, i.e., the aging-
associated loss of muscle mass [84], an effect possibly 
due to the recovery of the altered Akt/mTOR signaling 
in muscles of aged rats [85]. Correspondingly, other 
groups have recently reported that BCAAs decrease 
protein breakdown and protect against dexamethasone-
induced soleus muscle atrophy in rats [86]. BCAAem-
mediated improvement of muscle functional capacity 
was further enhanced by exercise training [12]. Exercise 
promotes longevity and is the best intervention to 
alleviate and reverse sarcopenia and frailty in the 
elderly [87].  It has been reported that concurrent  intake 
of antioxidants (vitamin C and E) abolished some 
health-promoting effects of exercise in humans, by 
preventing the induction of the ROS sensors PGC-1α/β 
and consequent activation of  ROS defense [88]. Our 
results suggest that the BCAAem could meet the need 
for a safe PGC-1α inducer in sarcopenia treatment [87] 
  
www.impactaging.com                  471                                             AGING,  May 2011, Vol.3 No.5
and a valid substitute for dietary supplementation with 
antioxidants in active elderly people.  
 
The BCAAs leucine and valine have been also reported 
to prevent muscle atrophy in mice bearing a cachexia-
inducing tumor [89]. Given the possible benefits of 
BCAAs in cancer patients, it would be of relevance to 
determine their effects on neoplastic cell growth. 
Dietary amino acids, incluning BCAAs, have been used 
in cancer models with mixed results [90-92]. Anyway, 
convincing data demonstrate that BCAA treatment does 
not directly potentiate neoplastic cell growth and may 
actually diminish neoplastic cell proliferation at 
supraphysiological concentrations [93]. Further 
investigation is needed to examine the effects of amino 
acid mixtures with different BCAA composition on 
normal and tumor cell proliferation. 
 
Additional observations deal with the capability of the 
BCAAem formula to ameliorate myocardial 
dysfunction  in diabetic rats [94] and to maintain the 
health of kidney in aged rats [95]. In particular, when 
administered orally at the beginning of rat senescence, 
BCAAem induces eNOS and vascular endothelial 
growth factor in the kidney, thus increasing 
vascularization and reducing kidney fibrosis. Improved 
vascularization and increased collagen deposition and 
fibroblast proliferation seem also to be involved in the 
cutaneous wound healing obtained with topical 
application of BCAAs and other essential amino acids 
in aged rats [96].  
 
Again, BCAAs compete for large, neutral amino acid 
transport at the blood–brain barrier and can influence 
brain neurotrasmitter synthesis [97]. Experimental 
studies show that BCAAs have favourable effects on 
cognitive functions. BCAA supplementation has been 
reported to improve cognitive performance in active 
dogs, with greater benefit to senior dogs [98].  BCAA 
transamination  plays an essential role in the synthesis 
of glutamate and subsequently of GABA. Cole et al. 
[99] evaluated mice subjected to traumatic brain injury, 
and found a significant reduction in BCAA 
concentration and neurotransmitter changes in the 
hippocampus.  Dietary delivery of BCAAs to brain-
injured mice restored hippocampal BCAA levels, 
synaptic glutamate and GABA pools and net synaptic 
efficacy, and eradicated injury-induced cognitive 
impairment [99].  
 
Human studies: promising evidence 
Emerging metabolomic technologies make it feasible to 
investigate the metabolic status of the whole human 
organism in high-throughput applications. Newgard et 
al. [100] studied subjects that become obese on a typical 
Western diet (with high fat and protein content). By 
metabolic profiling, they identified a cluster of obesity-
related changes in specific amino acids that was 
associated with insulin resistance. In particular, 
circulating levels of the BCAAs were higher in obese 
compared to lean subjects [100]. Obesity was also 
associated with decreases in bioavailable IGF-1. The 
authors suggested that, in the context of overnutrition 
and low IGF-1 levels, circulating BCAAs rise, leading 
to an overload of BCAA catabolism that contributes to 
insulin resistance in obese subjects. 
 
A more recent nested case-control study in the 
Framingham Offspring Study has investigated whether 
metabolite profiles could predict the development of 
type 2 diabetes [101]. Fasting concentrations of BCAAs 
and of two aromatic amino acids, phenylalanine and 
tyrosine, were found elevated up to 12 years before the 
onset of diabetes in high risk subjects as compared to 
propensity-matched control subjects. The strongest risk 
of future diabetes was associated to a combination of 
three amino acids, namely isoleucine, phenylalanine and 
tyrosine. In a more heterogeneous study sample, obtained 
by looking at a random set of controls from the 
Framingham cohort (having lower baseline body mass 
index and fasting glucose values compared to the case-
control sample), the relative risk associated with elevated 
amino acids, though still significant, was attenuated 
[101]. The authors recognize that contrasting data exist 
on BCAA effects on glucose homeostasis and that further 
investigation is necessary to assess whether amino acids 
may be markers or effectors of insulin resistance.  
 
On the other hand, sparse studies in wrestlers and in 
obese subjects have shown that BCAA supplementation 
exerts beneficial effects on body weight and body fat 
[102]. Most recently, the population-based International 
Study of Macro-/Micronutrients and Blood Pressure 
(INTERMAP) provided a unique opportunity to 
evaluate the effects of dietary BCAAs across different 
cultures. This high-quality study demonsrated that a 
higher BCAA intake is associated with a lower 
prevalence of being overweight or obese in middle-aged 
individuals from East Asian and Western countries 
[102]. In this line, Solerte et al. studied the effects of a 
balanced amino acid formula corresponding to the 
BCAAem in a long-term randomized study of elderly 
subjects with type 2 diabetes and found improved 
metabolic control (i.e., reduced glycated hemoglobin 
[HbA1c] ) and insulin sensitivity [103]. Noteworthy, 
BCAAs effectively reduce insulin resistance in patients 
with chronic viral liver disease [104], and the health 
effects of BCAA supplementation in patients affected 
by liver disorders, including cirrhosis, was demons-
trated in several reports [105-107].  
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A variety of amino acid mixtures have been used to 
restore the protein content of defective tissues, 
especially of skeletal muscles, in aged subjects [108, 
109]. Dillon et al. [108] reported that 3-month 
supplementation with essential amino acids increases 
IGF-1 muscle levels and lean body mass in aged 
women, without affecting kidney function. The acute 
anabolic response to this supplementation (increased 
muscle protein fractional synthesis rate) was maintained 
over time, suggesting the possibility to improve skeletal 
muscle trophism in long-term treatment [108]. Various 
BCAA dietary supplements have been reported to 
reduce sarcopenia  in elderly subjects. In a randomized 
trial involving 41 subjects with sarcopenia aged 66 to 
84 years, intake of the BCAAem formula increased 
muscle mass, reduced tumor necrosis factor-α, and 
improved insulin sensitivity [110]. As a result, leucine-
enriched balanced amino acid supplements are now 
considered as part of the nutritional recommendations 
for the management of sarcopenia [111]. 
 
Amino acid supplementation also inhibits inflammatory 
































present a promising therapeutic approach, particularly 
in the presence of the so-called wasting syndrome 
[112]. Accordingly, supplementation with the BCAAem 
formula improves exercise capacities in elderly subjects 
affected by chronic heart failure [113]. The latter effect 
was detectable also in aged individuals without evident 
disorders [114].  
 
Certainly of interest are the recent reports that 
BCAAem intake reduces by 30% the incidence of 
infections acquired in geriatric long-term rehabilitation 
centers [115], increases the serum albumin and total 
proteins in hemodialysis patients, with reduction of 
inflammation markers and correction of anemia [116], 
and improves gas exchange and cognitive function 
score in patients with severe chronic obstructive 
pulmonary disease [117]. Equally important, in keeping 
with intriguing experimental data [99], parenteral 
supplementation of BCAAs was shown to enhance the 
cognitive recovery of patients with traumatic brain 
injury [118], even when on a vegetative or minimally 
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Conclusions  and perspectives 
 
A body of recent evidence suggest that amino acids, and 
in particular BCAAs, behave as evolutionary conserved 
modulators of lifespan of different organisms, ranging 
from yeast to mammals. Our data  demonstrate that oral 
intake of a BCAA-enriched balanced amino acid 
mixture improves motor coordination and endurance 
and promotes longevity of male mice [12]. The key role 
of BCAAem on mitochondrial biogenesis, cell energy 
metabolism, and ROS scavenging systems, through the 
modulation of the mTOR/eNOS pathways, may explain 
most of the beneficial actions of this supplementation. 
Importantly, among the many genetic and 
pharmacological treatments that extend longevity in 
diverse animal models, BCAA supplementation has the 
add-on value to prolong animal health and functional 
capacities. Accordingly, likewise exercise, BCAAem 
does not affect maximum lifespan, but increases the 
median lifespan, an indicator that specific diseases have 
been prevented. Geriatricians have long recognized that 
disability, frailty, and age-related disease onset are 
critical issues that need to be addressed in older 
populations. Hence, the concept of healthspan has 
emerged as a key end point for geriatric studies to 
translate experimental findings into realistic clinical 
interventions [120]. A number of preclinical and clinical 
reports, here reviewed, supports the use of dietary 
supplementation with balanced amino acid formulas 
containing BCAAs to prevent disability and prolong 
healthy life expectancy of elderly subjects (see 
summary in Fig. 3). 
 
A broad range of questions await answers. The first 
point to be clarified is the role that specific amino acid 
signatures can play, directly or indirectly, in the CR 
effects on healthspan. Next, taken into account the 
contradictory results that arise from leucine 
administration, there is need to investigate which amino 
acid (or specific amino acid combination) is required for 
the beneficial effects seen in mammals. Not last in 
importance, large, randomized clinical trials are 
necessary to assess the safety and efficacy of 
BCAA/amino acid supplementation for the prevention 
and treatment of the disabling consequences of energy 
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